Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists scan brains of people with autism and fragile x to spot key differences

NCT ID NCT02719951

Knowledge-focused Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study used special PET and MRI scans to look at brain activity in 27 men with autism, Fragile X syndrome, or no condition. The goal was to measure a brain chemical called glutamate, which helps nerve cells communicate. Researchers hope this will reveal how brain signaling differs in these conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
[18F]FPEB (a radioactive tracer for PET scans)
What this could lead to
If successful, this could help researchers better understand brain chemistry differences in autism and Fragile X syndrome.
What could go wrong
This is a small, early-phase imaging study, not a treatment trial. It may not lead to direct benefits for patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

27 people

The number who actually took part.

Start date

Apr 2016

Finished

May 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male * Between 18 years-old and 45 years-old * Informed, written consent obtained from patient or his representant * Subject with an affiliation to French social security * For autistic patient : patient with diagnosis of ASD (Autistic Spectrum Disorders) following DSM-IV or DSM-5 criteria with recommended tools (ADI-R and/or ADOS) * For FXS patient : diagnosis of FXS and confirmation of total mutation of FMR1 Exclusion Criteria: * Contraindications to MRI * Excessive use of alcohol or drug, or addiction to alcohol or drug during last 6 months * Any unstable or uncontrolled disease, clinically significant * Participation to an other experimental protocol with drug or irradiant exam * Person under exclusion period because of previous participation to an other experimental protocol * Person under temporary guardianship * Forbidden treatments : any psychotropic treatment for 4 last weeks before PET exam and changing durably glutaminergic transmission directly or undirectly * For healthy subjects : adult under guardianship, medical history of central nervous system disease, medical history of attention deficit hyperactivity disorder, past or present psychiatric or neurologic disorder (MINI DSM-IV)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autism autism spectrum disorder fragile X syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autism Fragile X syndrome (FXS) Healthy volunteers

Contacts and locations

Locations

  • CHU Tours

    Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.